Press coverage about Sarepta Therapeutics (NASDAQ:SRPT) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sarepta Therapeutics earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.6751464896588 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program (finance.yahoo.com)
- Sarepta Therapeutics, Inc. (SRPT) stock ends 25.19% higher to 50- SMA – The Stocks News (press release) (thestocksnews.com)
- Credit Suisse Group Boosts Sarepta Therapeutics (SRPT) Price Target to $100.00 (americanbankingnews.com)
- Sarepta Therapeutics (SRPT) Raised to “Strong-Buy” at BidaskClub (americanbankingnews.com)
- Sarepta Therapeutics (SRPT) PT Raised to $95.00 at SunTrust Banks (americanbankingnews.com)
SRPT has been the topic of a number of recent research reports. Janney Montgomery Scott initiated coverage on Sarepta Therapeutics in a report on Wednesday, January 3rd. They set a “buy” rating and a $75.00 price objective on the stock. HC Wainwright set a $75.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Oppenheimer restated a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. Finally, Nomura upped their target price on Sarepta Therapeutics to $96.00 and gave the stock a “buy” rating in a research note on Friday, March 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Sarepta Therapeutics presently has an average rating of “Buy” and a consensus target price of $75.31.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up $1.74 during trading on Tuesday, hitting $80.52. The stock had a trading volume of 867,208 shares, compared to its average volume of 1,675,437. The company has a debt-to-equity ratio of 0.54, a current ratio of 13.91 and a quick ratio of 12.96. The company has a market cap of $5,258.05, a price-to-earnings ratio of -100.65 and a beta of 1.52. Sarepta Therapeutics has a 12-month low of $28.14 and a 12-month high of $84.37.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). The firm had revenue of $57.30 million for the quarter, compared to the consensus estimate of $57.33 million. Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. Sarepta Therapeutics’s revenue for the quarter was up 961.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.71) earnings per share. analysts expect that Sarepta Therapeutics will post -1.18 EPS for the current year.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.